Chemed Corporation 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014; filed February 27, 2015. This is an annual filing, not a standalone fourth-quarter report. Chemed operates through VITAS, a hospice and palliative-care provider, and Roto-Rooter, a plumbing and drain-cleaning business.
Financial performance and position
- The supplied filing text incorporates the financial statements and management’s discussion from the 2014 Annual Report, but does not reproduce their results. It therefore does not provide clear values here for revenue, net income, cash flow, margins, cash balances, or year-over-year changes in those measures.
- Long-term debt was approximately $147.5 million at December 31, 2014; the filing describes all outstanding debt as variable-rate. A 100-basis-point rate change would change annual interest expense by $100,000 for each $10 million borrowed under the credit facility.
- VITAS depends heavily on government reimbursement: approximately 90% of its revenue came from Medicare, and more than 90% of its net patient service revenue came from Medicare and Medicaid. Medicaid accounted for 5% of VITAS revenue in 2014.
- VITAS’s overall Medicare hospice payment cap was $26,725.79 per admission for the year ended October 31, 2014. Its reimbursement is primarily per diem, making profitability sensitive to care costs, patient mix, and compliance with payment rules.
- Chemed repurchased 1,182,934 shares during 2014 under its February 2011 repurchase program. The program had $11.8 million remaining at year-end. Quarterly dividends per share were $0.20, $0.20, $0.22, and $0.22 in 2014; future dividends depend on earnings, financial condition, and debt covenants.
- The company recorded a $1.7 million accrual for potential environmental cleanup and related costs tied to the former DuBois Chemicals business. It was contingently liable for up to an additional $14.9 million; management did not consider payment of that additional amount probable and recorded no provision for it.
Changes versus the prior comparable period
- The provided text does not include comparable 2013 and 2014 consolidated revenue, earnings, cash-flow, or margin figures, so the direction and magnitude of operating changes cannot be established from this text.
- Quarterly dividends increased from $0.18, $0.18, $0.20, and $0.20 in 2013 to $0.20, $0.20, $0.22, and $0.22 in 2014.
- Chemed’s reported cumulative total stockholder return index rose from 166.37 at December 31, 2013 to 231.47 at December 31, 2014 (base 100 at December 31, 2009). The corresponding 2014 index values were 205.14 for the S&P 500 and 214.87 for the Dow Jones Diversified Industrials Index.
- Net costs related to the federal VITAS matter and related regulatory matters were $2.1 million in both 2014 and 2013, versus $1.2 million in 2012.
Outlook, risks, contingencies, and unusual items
- The supplied text gives no quantified earnings or revenue guidance. Management notes that VITAS faces potential pressure from government reimbursement changes, inflation in labor and supply costs, patient eligibility scrutiny, and payment caps. A 2% Medicare reimbursement reduction had been implemented effective April 1, 2013.
- VITAS faces substantial regulatory and litigation exposure. A federal False Claims Act action and consolidated related claims allege improper Medicare billing, including claims involving continuous home care and hospice eligibility. The court denied most of defendants’ motion to dismiss in September 2014, except for claims filed before July 24, 2002. The government seeks treble damages, penalties, costs, and interest. The company says it intends to defend the matters vigorously; the filing does not provide a clear quantified loss estimate.
- Two shareholder derivative lawsuits concerning alleged oversight failures and improper claims were consolidated in Delaware in February 2015. The defendants intended to renew a motion to dismiss after the operative complaint was filed.
- Other key risks include VITAS’s reliance on Medicare and Medicaid, nurse shortages and wage pressure, claims audits and recoupments, licensing and certificate-of-need requirements, and the concentration of major VITAS operations in hurricane-prone south Florida. Roto-Rooter is exposed to fragmented competition, weather variability, skilled-worker availability, and franchise and licensing regulation.
- Chemed’s debt covenants restrict certain borrowing, acquisitions, investments, distributions, and other activities. Variable interest rates create additional exposure. The filing states that environmental compliance costs for 2015 and 2016 were not expected to be material, while cautioning that unforeseen actions could require additional spending.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting during the fourth quarter of 2014.
Important facts for investors to verify
- Review the incorporated 2014 Annual Report for audited consolidated results, segment performance, cash flows, liquidity, margins, and 2013 comparisons; those figures are not included in the supplied text.
- Check the latest status and any quantified exposure or reserve updates for the VITAS False Claims Act matters, related government investigations, and derivative litigation.
- Confirm year-end cash, debt maturities, covenant headroom, and sensitivity to variable interest rates against the full financial statements and credit agreement.
- Assess Medicare hospice reimbursement and cap exposure, claims-review outcomes, and VITAS patient eligibility and service mix.
- Monitor environmental cleanup estimates and any changes to the DuBois contingent liability.